Bausch+Lomb Results Presentation Deck
Total Bausch+Lomb P&L¹ (Non-GAAP)²
Bausch + Lomb
Vision Care Revenue
Surgical Revenue
Ophthalmic Pharmaceuticals
Revenue
Total Revenue
Adj. Gross Profit²
Adj. Gross Margin ²
R&D
R&D percent of Revenues
Adj. SG&A²
Adj. SG&A percent of Revenues³
Adj. EBITA²
Depreciation
Stock Based Compensation
Adj. EBITDA 2,3
Adj. EBITDA Margin²
Adj. Net Income²
Adj EPS 3,4
2Q22
$589M
$184 M
$168M
$941 M
$562M
59.7%
$75M
8.0%
$362M
38.5%
$125M
$34M
$11M
$182M
19.3%
$103M
$0.29
2Q21
$556M
$185M
$193M
$934M
$567M
60.7%
$71M
7.6%
$352M
37.7%
$144M
$34M
$15M
$200M
21.4%
$116M
$0.33
Reported Change
6%
(1%)
(13%)
1%
(1%)
(100 bps)
(6%)
(3%)
(13%)
0%
(27%)
(9%)
(11%)
1. Products with sales outside the United States impacted by F/X changes.
BAUSCH + LOMB 2. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios.
3. Includes transactional FX and NCI.
4. On a proforma basis after giving effect to the IPO.
Constant
Currency²
11%
5%
(10%)
6%
3%
(8%)
(7%)
(8%)
6%
(27%)
(7%)
(8%)
Organic Change²
11%
7%
(10%)
6%
+6% organic revenue growth ¹,2
Investment YTD in R&D +$14M,
~8% of revenue
Continue to maintain a
disciplined approach to cost
management and leverage our
infrastructure
8View entire presentation